On the other hand, in recent years, as genetic knowledge about ovarian cancer has rapidly increased, poly (ADP-ribose) polymerase (PARP) inhibitors were introduced to treat ovarian cancer, and promising results were shown in patients with breast cancer gene 1 and 2 (BRCA1/2) mutation carriers [6,15]. The gene discussed is BRCA1; the disease is ovarian cancer.